This WHO report, produced in collaboration with
Member States and other partners, provides as accurate
a picture as is presently possible of the magnitude of
AMR and the current state of surveillance globally.
The report focuses on antibacterial resistance (ABR)
in common bacterial pathogens. Why? There is a
major gap in knowledge about the magnitude of this
problem and such information is needed to guide
urgent public health actions. ABR is complex and
multidimensional. It involves a range of resistance
mechanisms affecting an ever-widening range of
bacteria, most of which can cause a wide spectrum
of diseases in humans and animals.
One important finding of the report, which will serve
as a baseline to measure future progress, is that there
are many gaps in information on pathogens of major
public health importance. In addition, surveillance of
ABR generally is neither coordinated nor harmonized,
compromising the quality and representativeness of
Nonetheless, the report makes a clear case that
resistance to common bacteria has reached alarming
levels in many parts of the world suggesting that
many of the available treatment options for common
infections in some settings are becoming ineffective.
Furthermore, systematic reviews of the scientific
evidence show that ABR has a negative impact on
outcomes for patients and health-care expenditures.
Generally, surveillance in TB, malaria and HIV to detect
resistance, determine disease burden and monitor
public health interventions is better established and
experiences from these programmes are described
in the report, so that lessons learnt can be applied
to ABR and opportunities for collaboration identified.